These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 34799547)
1. Prognostic Value of E2F Transcription Factor Expression in Pancreatic Adenocarcinoma. Luo L; Zhang G; Wu T; Wu G Med Sci Monit; 2021 Nov; 27():e933443. PubMed ID: 34799547 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of Prognostic and Immune Infiltrates for E2F Transcription Factors in Human Pancreatic Adenocarcinoma. Liu XS; Gao Y; Liu C; Chen XQ; Zhou LM; Yang JW; Kui XY; Pei ZJ Front Oncol; 2020; 10():606735. PubMed ID: 33604289 [TBL] [Abstract][Full Text] [Related]
3. Integrate analysis of the promote function of Cell division cycle-associated protein family to pancreatic adenocarcinoma. Xing C; Wang Z; Zhu Y; Zhang C; Liu M; Hu X; Chen W; Du Y Int J Med Sci; 2021; 18(3):672-684. PubMed ID: 33437202 [No Abstract] [Full Text] [Related]
4. Expression, Prognosis, and Immune Infiltrates Analyses of E2Fs in Human Brain and CNS Cancer. Liao P; Han S; Qu H Biomed Res Int; 2020; 2020():6281635. PubMed ID: 33381564 [TBL] [Abstract][Full Text] [Related]
5. Bioinformatics analysis identified MMP14 and COL12A1 as immune-related biomarkers associated with pancreatic adenocarcinoma prognosis. Li Y; Su Z; Wei B; Qin M; Liang Z Math Biosci Eng; 2021 Jun; 18(5):5921-5942. PubMed ID: 34517516 [TBL] [Abstract][Full Text] [Related]
6. Expression patterns and prognostic values of the Jiang P; Zhang M; Gui L; Zhang K J Int Med Res; 2020 Dec; 48(12):300060520930113. PubMed ID: 33290118 [TBL] [Abstract][Full Text] [Related]
7. SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma. You W; Ke J; Chen Y; Cai Z; Huang ZP; Hu P; Wu X Front Immunol; 2022; 13():864244. PubMed ID: 35720314 [TBL] [Abstract][Full Text] [Related]
8. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma. Yan C; Niu Y; Li F; Zhao W; Ma L J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146 [TBL] [Abstract][Full Text] [Related]
9. Kuang W; Wang X; Ding J; Li J; Ji M; Chen W; Wang L; Yang P Front Immunol; 2022; 13():805311. PubMed ID: 35154122 [TBL] [Abstract][Full Text] [Related]
10. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Huang X; Zhang G; Tang T; Liang T Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511 [TBL] [Abstract][Full Text] [Related]
11. Integrated analysis identified the role of three family members of ARHGAP in pancreatic adenocarcinoma. Fei H; Shi X; Sun D; Yang H; Wang D; Li K; Si X; Hu W Sci Rep; 2024 May; 14(1):11790. PubMed ID: 38783033 [TBL] [Abstract][Full Text] [Related]
12. Prognostic values of Manicum T; Ni F; Ye Y; Fan X; Chen BC Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30487158 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer. Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H Front Immunol; 2021; 12():769425. PubMed ID: 34804059 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of CENPL mRNA potentially regulated by miR-340-3p predicts the prognosis of pancreatic cancer patients. Cui Z; Du L; Wang J; Li Z; Xu J; Ou S; Li D; Li S; Hu H; Chen G; Wu Z BMC Cancer; 2022 Dec; 22(1):1354. PubMed ID: 36572856 [TBL] [Abstract][Full Text] [Related]
15. High Lv S; Zhang G; Xie L; Yan Z; Wang Q; Li Y; Zhang L; Han Y; Li H; Du Y; Yang Y; Guo X Biomed Res Int; 2020; 2020():2585862. PubMed ID: 32185195 [TBL] [Abstract][Full Text] [Related]
16. LINC01232 Sponges Multiple miRNAs and Its Clinical Significance in Pancreatic Adenocarcinoma Diagnosis and Prognosis. Du W; Lei C; Wang Y; Ding Y; Tian P Technol Cancer Res Treat; 2021; 20():1533033820988525. PubMed ID: 33506742 [TBL] [Abstract][Full Text] [Related]
17. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
18. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma. Chen Y; Lin X; Zou X; Qian Y; Liu Y; Wang R; Wang X; Yu X; Liu C; Cheng H BMC Gastroenterol; 2023 Apr; 23(1):113. PubMed ID: 37024802 [TBL] [Abstract][Full Text] [Related]
19. LACTB mRNA expression is increased in pancreatic adenocarcinoma and high expression indicates a poor prognosis. Xie J; Peng Y; Chen X; Li Q; Jian B; Wen Z; Liu S PLoS One; 2021; 16(1):e0245908. PubMed ID: 33507917 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Clear Cell Renal Cell Carcinoma. Zhang C; Cui Y; Wang G; Zhao W; Zhao H; Huang X; Zhang M; Li W J Healthc Eng; 2021; 2021():5790416. PubMed ID: 34531966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]